Targeted immunotherapy for hairy cell leukemia

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1888-1890

  Park, Jae H ^a   Levine, Ross L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CASPASE 3; CASPASE 9; CD22 ANTIGEN; DENILEUKEIN DIFTITOX; IMMUNOTOXIN; MOXETUMOMAB PASUDOTOX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOSOL; CYTOTOXICITY; DRUG EFFICACY; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; HAIRY CELL LEUKEMIA; HUMAN; MARGINAL ZONE LYMPHOMA; MUTAGENESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84864001182     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.8313     Document Type: Article

References (30)

1. Kreitman RJ, Tallman MS, Robak T, et al: Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30: 1822-1828, 2012
2. Nitschke L, Carsetti R, Ocker B, et al: CD22 is a negative regulator of B-cell receptor signalling. Curr Biol 7:133-143, 1997 (Pubitemid 27155622)
3. Dörken B, Moldenhauer G, Pezzutto A, et al: HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 136:4470-4479, 1986 (Pubitemid 16090664)
4. Vaickus L, Ball ED, Foon KA: Immune markers in hematologic malignancies. Crit Rev Oncol Hematol 11:267-297, 1991
5. Matsushita K, Margulies I, Onda M, et al: Soluble CD22 as a tumor marker for hairy cell leukemia. Blood 112:2272-2277, 2008
6. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003 (Pubitemid 46606284)
7. Leonard JP, Coleman M, Ketas JC, et al: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004 (Pubitemid 39100467)
8. Shan D, Press OW: Constitutive endocytosis and degradation of CD22 by human B cells. J Immunol 154:4466-4475, 1995
9. Bonardi MA, French RR, Amlot P, et al: Delivery of saporin to human B-cell lymphoma using bispecific antibody: Targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res 53:3015-3021, 1993 (Pubitemid 23210305)
10. Kreitman RJ, Pastan I: Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem J 307:29-37, 1995
11. Siegall CB, Chaudhary VK, FitzGerald DJ, et al: Functional analysis of domains II, Ib, and III of Pseudomonas exotoxin. J Biol Chem 264:14256-14261, 1989 (Pubitemid 19214253)
12. Decker T, Oelsner M, Kreitman RJ, et al: Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood 103:2718-2726, 2004 (Pubitemid 38393030)
13. Pastan I: Immunotoxins containing Pseudomonas exotoxin A: A short history. Cancer Immunol Immunother 52:338-341, 2003
14. Razi N, Varki A: Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci U S A 95:7469-7474, 1998 (Pubitemid 28293276)
15. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129, 2001
16. Collins BE, Blixt O, Han S, et al: High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol 177:2994-3003, 2006 (Pubitemid 44277815)
17. Kreitman RJ, Margulies I, Stetler-Stevenson M, et al: Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin Cancer Res 6:1476-1487, 2000 (Pubitemid 30226237)
18. Salvatore G, Beers R, Margulies I, et al: Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res 8:995-1002, 2002 (Pubitemid 35177347)
19. Chowdhury PS, Pastan I: Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol 17:568-572, 1999 (Pubitemid 29262920)
20. Yelton DE, Rosok MJ, Cruz G, et al: Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis. J Immunol 155:1994-2004, 1995
21. Yang WP, Green K, Pinz-Sweeney S, et al: CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J Mol Biol 254:392-403, 1995 (Pubitemid 26001779)
22. Low NM, Holliger PH, Winter G: Mimicking somatic hypermutation: Affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J Mol Biol 260:359-368, 1996 (Pubitemid 26254116)
23. de Kruif J, Boel E, Logtenberg T: Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J Mol Biol 248:97-105, 1995
24. Soler-Rodríguez AM, Ghetie MA, Oppenheimer-Marks N, et al: Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: Implications for vascular leak syndrome. Exp Cell Res 206:227-234, 1993 (Pubitemid 23212940)
25. Mansfield E, Amlot P, Pastan I, et al: Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90:2020-2026, 1997 (Pubitemid 27377315)
26. Onda M, Beers R, Xiang L, et al: An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105:11311-11316, 2008
27. Onda M, Beers R, Xiang L, et al: Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 108:5742-5747, 2011
28. Hershfield MS, Buckley RH, Greenberg ML, et al: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316:589-596, 1987 (Pubitemid 17024481)
29. Yeung VP, Chang J, Miller J, et al: Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 172:6658-6665, 2004 (Pubitemid 38669101)
30. Schirrmann T, Krauss J, Arndt MA, et al: Targeted therapeutic RNases (ImmunoRNases). Expert Opin Biol Ther 9:79-95, 2009